U.S. Same Facility Revenue Grows
6.1%
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced
financial results for the first quarter ended March 31, 2019.
The Company reported revenue of $760.6 million for the first
quarter of 2019, a 2.5% increase compared with $742.2 million for
the first quarter of 2018. Net income attributable to Acadia
stockholders was $29.5 million, or $0.34 per diluted share, for the
first quarter of 2019 compared with $50.8 million, or $0.58 per
diluted share, for the first quarter of 2018. Results for the first
quarter of 2019 include transaction-related expenses of $4.3
million and the income tax effect of adjustments to income of $0.5
million based on a tax rate of 16.6%. Adjusted income attributable
to Acadia stockholders was $34.3 million, or $0.39 per diluted
share, for the first quarter of 2019. Results for the first quarter
of 2018 included a tax benefit of $10.5 million due to the Tax Cuts
and Jobs Act of 2017, transaction-related expenses of $4.8 million,
debt extinguishment costs of $0.9 million, and the income tax
effect of adjustments to income of $0.9 million based on a tax rate
of 15.9%. Adjusted income attributable to Acadia stockholders for
the first quarter of 2018 was $45.2 million, or $0.52 per diluted
share.
A reconciliation of all non-GAAP financial results in this
release appears beginning on page 8.
“We are pleased to report a solid start to 2019 with our first
quarter financial and operating results in line with expectations,”
said Debbie Osteen, Chief Executive Officer of Acadia Healthcare
Company. “Our U.S. operations performed well with favorable trends
in key operating metrics. The results from our U.K. operations
showed consistent top line growth with revenue within our
anticipated range. We remain focused on implementing our plans to
improve the operating performance of our U.K. facilities.
“We continued to execute our growth strategy by expanding our
service offerings and capacity with the addition of 260 beds during
the first quarter. These expansions included the addition of 100
beds to existing facilities and 160 beds relating to two previously
announced de novo facilities, Mount Carmel Behavioral Health, a
joint venture, in Columbus, Ohio, and Rio Vista Behavioral Health
in El Paso, Texas. On February 15, 2019, we completed two
acquisitions – The Whittier Pavilion, a 71-bed inpatient
psychiatric hospital located in Haverhill, Massachusetts, and
Mission Treatment, a system of nine comprehensive treatment centers
that provide medication-assisted treatment and counseling for
people struggling with narcotics addiction in California, Nevada,
Arizona and Oklahoma. Exclusive of acquisitions, we expect to add
approximately 700 beds to existing and new facilities during 2019,”
added Osteen.
The Company’s total same facility revenue increased 5.6% for the
first quarter of 2019 compared with the first quarter of 2018,
including a 2.8% increase in patient days and a 2.7% increase in
revenue per patient day. Total same facility EBITDA margin declined
150 basis points to 22.7%. U.S. same facility revenue rose 6.1%, on
a 4.3% increase in patient days and a 1.7% increase in revenue per
patient day. U.S. same facility EBITDA margin was consistent with
the first quarter last year at 26.1%. U.K. same facility revenue
grew 4.7% for the first quarter of 2019 from the first quarter last
year, including a 0.9% increase in patient days and a 3.7% increase
in revenue per patient day. U.K. same facility EBITDA margin
declined 430 basis points to 16.3%. Acadia’s consolidated adjusted
EBITDA for the first quarter of 2019 was $136.0 million, compared
with $145.7 million for the first quarter of 2018.
Osteen added, “As we noted on our fourth quarter 2018 conference
call, Acadia’s senior management team and Board of Directors are
conducting a strategic review of our entire operations, and we
expect to provide an update of this review in late May.”
Acadia today affirmed its previously established financial
guidance for 2019, as follows:
- Revenue for 2019 in a range of $3.15
billion to $3.2 billion;
- Adjusted EBITDA for 2019 in a range of
$610 million to $630 million;
- Adjusted earnings per diluted share for
2019 in a range of $2.15 to $2.30; and
- An exchange rate of $1.30 per British
Pound Sterling and a tax rate of approximately 16%.
The Company’s guidance does not include the impact of any future
acquisitions or transaction-related expenses.
EBITDA is defined as net income adjusted for net income
attributable to noncontrolling interests, provision for (benefit
from) income taxes, net interest expense and depreciation and
amortization. Adjusted EBITDA is defined as EBITDA adjusted for
equity-based compensation expense, transaction-related expenses and
debt extinguishment costs. Adjusted income is defined as net income
adjusted for transaction-related expenses, tax reform impact, debt
extinguishment costs and income tax effect of adjustments to
income.
Acadia will hold a conference call to discuss its first quarter
2019 financial results at 9:00 a.m. Eastern Time on Wednesday,
May 1, 2019. A live webcast of the conference call will be
available at www.acadiahealthcare.com in the “Investors” section of
the website. The webcast of the conference call will be available
through May 15, 2019.
Risk Factors
This news release contains forward-looking statements.
Generally, words such as “may,” “will,” “should,” “could,”
“anticipate,” “expect,” “intend,” “estimate,” “plan,” “continue,”
and “believe” or the negative of or other variation on these and
other similar expressions identify forward-looking statements.
These forward-looking statements are made only as of the date of
this news release. We do not undertake to update or revise the
forward-looking statements, whether as a result of new information,
future events or otherwise. Forward-looking statements are based on
current expectations and involve risks and uncertainties and our
future results could differ significantly from those expressed or
implied by our forward-looking statements. Factors that may cause
actual results to differ materially include, without limitation,
(i) potential difficulties operating our business in light of
political and economic instability in the U.K. and globally
relating to Brexit; (ii) the impact of fluctuations in foreign
exchange rates, including the devaluation of the British Pound
Sterling (GBP) relative to the U.S. Dollar (USD); (iii) Acadia’s
ability to complete acquisitions and successfully integrate the
operations of acquired facilities; (iv) Acadia’s ability to add
beds, expand services, enhance marketing programs and improve
efficiencies at its facilities; (v) potential reductions in
payments received by Acadia from government and third-party payors;
(vi) the occurrence of patient incidents and governmental
investigations, which could adversely affect the price of our
common stock and result in substantial fines and incremental
regulatory burdens; (vii) the risk that Acadia may not generate
sufficient cash from operations to service its debt and meet its
working capital and capital expenditure requirements; and (viii)
potential operating difficulties, labor costs, client preferences,
changes in competition and general economic or industry conditions
that may prevent Acadia from realizing the expected benefits of its
business strategy. These factors and others are more fully
described in Acadia’s periodic reports and other filings with the
SEC.
About Acadia
Acadia is a leading provider of behavioral healthcare services.
At March 31, 2019, Acadia operated a network of 593 behavioral
healthcare facilities with approximately 18,100 beds in 40 states,
the United Kingdom and Puerto Rico. Acadia provides behavioral
health and addiction services to its patients in a variety of
settings, including inpatient psychiatric hospitals, specialty
treatment facilities, residential treatment centers and outpatient
clinics.
Acadia Healthcare Company, Inc. Condensed
Consolidated Statements of Income (Unaudited)
Three Months Ended March 31,
2019 2018 (In thousands, except per share
amounts) Revenue $ 760,617 $ 742,241
Salaries, wages and benefits (including
equity-based compensation expense of $6,101 and $6,919,
respectively)
429,579 411,528 Professional fees 57,007 54,018 Supplies 29,957
29,364 Rents and leases 20,307 20,288 Other operating expenses
93,865 88,231 Depreciation and amortization 40,580 39,773 Interest
expense, net 48,130 45,243 Debt extinguishment costs - 940
Transaction-related expenses 4,321 4,768
Total expenses 723,746 694,153
Income before income taxes 36,871 48,088 Provision for (benefit
from) income taxes 7,360 (2,786 ) Net income
29,511 50,874 Net income attributable to noncontrolling interests
(40 ) (55 ) Net income attributable to Acadia
Healthcare Company, Inc. $ 29,471 $ 50,819
Earnings per share attributable to Acadia Healthcare Company, Inc.
stockholders: Basic $ 0.34 $ 0.58 Diluted $ 0.34
$ 0.58 Weighted-average shares outstanding:
Basic 87,505 87,121 Diluted 87,694 87,294
Acadia
Healthcare Company, Inc. Condensed Consolidated Balance
Sheets (Unaudited) March
31, December 31, 2019 2018 (In
thousands) ASSETS Current assets: Cash and cash
equivalents $ 43,684 $ 50,510 Accounts receivable, net 331,851
318,087 Other current assets 76,979 81,820
Total current assets 452,514 450,417 Property and equipment,
net 3,173,052 3,107,766 Goodwill 2,441,999 2,396,412 Intangible
assets, net 89,796 88,990 Deferred tax assets 3,436 3,468
Derivative instrument assets 46,304 60,524 Operating lease
right-of-use assets 506,787 - Other assets 71,629
64,927 Total assets $ 6,785,517 $ 6,172,504
LIABILITIES AND EQUITY Current
liabilities: Current portion of long-term debt $ 36,503 $ 34,112
Accounts payable 116,666 117,740 Accrued salaries and benefits
108,546 113,299 Current portion of operating lease liabilities
27,984 - Other accrued liabilities 134,972
151,226 Total current liabilities 424,671 416,377 Long-term
debt 3,221,709 3,159,375 Deferred tax liabilities 76,922 80,372
Operating lease liabilities 504,753 - Other liabilities
122,188 154,267 Total liabilities 4,350,243
3,810,391 Redeemable noncontrolling interests 31,931 28,806 Equity:
Common stock 876 874 Additional paid-in capital 2,546,759 2,541,987
Accumulated other comprehensive loss (426,586 ) (462,377 ) Retained
earnings 282,294 252,823 Total equity
2,403,343 2,333,307 Total liabilities
and equity $ 6,785,517 $ 6,172,504
Acadia Healthcare Company, Inc. Condensed Consolidated
Statements of Cash Flows (Unaudited)
Three Months Ended March 31, 2019
2018 (In thousands) Operating activities: Net
income $ 29,511 $ 50,874
Adjustments to reconcile net income to
net cash provided by continuing operating activities:
Depreciation and amortization 40,580 39,773 Amortization of debt
issuance costs 2,888 2,525 Equity-based compensation expense 6,101
6,919 Deferred income taxes (666 ) 1,897 Debt extinguishment costs
- 940 Other 2,187 1,043 Change in operating assets and liabilities:
Accounts receivable, net (11,980 ) (18,793 ) Other current assets
(5,875 ) (13,216 ) Other assets 295 (1,268 ) Accounts payable and
other accrued liabilities (15,701 ) (3,368 ) Accrued salaries and
benefits (5,849 ) 4,802 Other liabilities 2,182
509 Net cash provided by continuing operating
activities 43,673 72,637 Net cash used in discontinued operating
activities - (287 ) Net cash provided by
operating activities 43,673 72,350
Investing
activities: Cash paid for acquisitions, net of cash acquired
(40,400 ) - Cash paid for capital expenditures (69,248 ) (70,327 )
Cash paid for real estate acquisitions (1,066 ) (4,293 ) Other
613 (4,066 ) Net cash used in investing
activities (110,101 ) (78,686 )
Financing activities:
Borrowings on revolving credit facility 71,573 - Principal payments
on long-term debt (8,246 ) - Common stock withheld for minimum
statutory taxes, net (1,327 ) (2,030 ) Other (3,497 )
(2,704 ) Net cash provided by (used in) financing activities 58,503
(4,734 ) Effect of exchange rate changes on cash
1,099 1,588 Net decrease in cash and
cash equivalents (6,826 ) (9,482 ) Cash and cash equivalents at
beginning of the period 50,510 67,290
Cash and cash equivalents at end of the period $ 43,684 $
57,808
Effect of acquisitions: Assets
acquired, excluding cash $ 44,028 $ - Liabilities assumed
(3,628 ) - Cash paid for acquisitions, net of cash
acquired $ 40,400 $ -
Acadia
Healthcare Company, Inc. Operating Statistics
(Unaudited, Revenue in thousands)
Three Months Ended March 31,
2019 2018 % Change Same Facility Results (a,c)
Revenue $ 723,807 $ 685,226 5.6% Patient Days 1,123,008 1,092,369
2.8% Admissions 43,727 41,141 6.3% Average Length of Stay (b) 25.7
26.6 -3.3% Revenue per Patient Day $ 645 $ 627 2.7% EBITDA margin
22.7 % 24.2 % -150 bps U.S. Same Facility Results (a)
Revenue $ 475,018 $ 447,584 6.1% Patient Days 625,554 599,510 4.3%
Admissions 41,343 38,705 6.8% Average Length of Stay (b) 15.1 15.5
-2.3% Revenue per Patient Day $ 759 $ 747 1.7% EBITDA margin 26.1 %
26.1 % 0 bps U.K. Same Facility Results (a,c) Revenue $
248,789 $ 237,642 4.7% Patient Days 497,454 492,859 0.9% Admissions
2,384 2,436 -2.1% Average Length of Stay (b) 208.7 202.3 3.1%
Revenue per Patient Day $ 500 $ 482 3.7% EBITDA margin 16.3 % 20.6
% -430 bps U.S. Facility Results Revenue $ 487,960 $
462,405 5.5% Patient Days 640,324 612,889 4.5% Admissions 42,252
38,932 8.5% Average Length of Stay (b) 15.2 15.7 -3.7% Revenue per
Patient Day $ 762 $ 754 1.0% EBITDA margin 24.4 % 25.3 % -90 bps
U.K. Facility Results (c) Revenue $ 272,657 $ 261,891 4.1%
Patient Days 664,393 665,571 -0.2% Admissions 2,758 2,762 -0.1%
Average Length of Stay (b) 240.9 241.0 0.0% Revenue per Patient Day
$ 410 $ 393 4.3% EBITDA margin 14.7 % 18.3 % -360 bps Total
Facility Results (c) Revenue $ 760,617 $ 724,296 5.0% Patient Days
1,304,717 1,278,460 2.1% Admissions 45,010 41,694 8.0% Average
Length of Stay (b) 29.0 30.7 -5.5% Revenue per Patient Day $ 583 $
567 2.9% EBITDA margin 20.9 % 22.8 % -190 bps (a) Results
for the periods presented exclude the elderly care division of our
U.K. operations and certain closed services. (b) Average length of
stay is defined as patient days divided by admissions. (c) Revenue
and revenue per patient day for the three months ended March 31,
2018 is adjusted to reflect the foreign currency exchange rate for
the comparable period of 2019 in order to eliminate the effect of
changes in the exchange rate. The exchange rate used in the
adjusted revenue and revenue per patient day amounts for the three
months ended March 31, 2018 is 1.30.
Acadia
Healthcare Company, Inc. Reconciliation of Net Income
Attributable to Acadia Healthcare Company, Inc. to Adjusted
EBITDA (Unaudited) Three
Months Ended March 31, 2019 2018 (in
thousands) Net income attributable to Acadia Healthcare
Company, Inc. $ 29,471 $ 50,819 Net income attributable to
noncontrolling interests 40 55 Provision for (benefit from) income
taxes 7,360 (2,786 ) Interest expense, net 48,130 45,243
Depreciation and amortization 40,580 39,773
EBITDA 125,581 133,104 Adjustments: Equity-based
compensation expense (a) 6,101 6,919 Transaction-related expenses
(b) 4,321 4,768 Debt extinguishment costs (c) -
940 Adjusted EBITDA $ 136,003 $ 145,731
See footnotes on page 10.
Acadia Healthcare
Company, Inc. Reconciliation of Adjusted Income Attributable
to Acadia Healthcare Company, Inc. to Net Income
Attributable to Acadia Healthcare Company, Inc.
(Unaudited) Three Months
Ended March 31, 2019 2018 (in thousands,
except per share amounts) Net income attributable to
Acadia Healthcare Company, Inc. $ 29,471 $ 50,819
Adjustments to income: Transaction-related expenses (b) 4,321 4,768
Tax reform impact (d) - (10,472 ) Debt extinguishment costs (c) -
940 Income tax effect of adjustments to income (e) 549
(861 ) Adjusted income attributable to Acadia Healthcare
Company, Inc. $ 34,341 $ 45,194 Weighted-average
shares outstanding - diluted 87,694 87,294
Adjusted income attributable to Acadia
Healthcare Company, Inc. per diluted share
$ 0.39 $ 0.52 See footnotes on page 10.
Acadia Healthcare Company, Inc. Footnotes We
have included certain financial measures in this press release,
including EBITDA, Adjusted EBITDA, and Adjusted income, which are
“non-GAAP financial measures” as defined under the rules and
regulations promulgated by the SEC. We define EBITDA as net income
adjusted for net income attributable to noncontrolling interests,
provision for (benefit from) income taxes, net interest expense and
depreciation and amortization. We define Adjusted EBITDA as EBITDA
adjusted for equity-based compensation expense, transaction-related
expenses and debt extinguishment costs. We define Adjusted income
as net income adjusted for transaction-related expenses, tax reform
impact, debt extinguishment costs, and income tax effect of
adjustments to income. EBITDA, Adjusted EBITDA, and Adjusted
income are supplemental measures of our performance and are not
required by, or presented in accordance with, generally accepted
accounting principles in the United States (“GAAP”). EBITDA,
Adjusted EBITDA, and Adjusted income are not measures of our
financial performance under GAAP and should not be considered as
alternatives to net income or any other performance measures
derived in accordance with GAAP or as an alternative to cash flow
from operating activities as measures of our liquidity. Our
measurements of EBITDA, Adjusted EBITDA, and Adjusted income may
not be comparable to similarly titled measures of other companies.
We have included information concerning EBITDA, Adjusted EBITDA,
and Adjusted income in this press release because we believe that
such information is used by certain investors as measures of a
company’s historical performance. We believe these measures are
frequently used by securities analysts, investors and other
interested parties in the evaluation of issuers of equity
securities, many of which present EBITDA, Adjusted EBITDA, and
Adjusted income when reporting their results. Our presentation of
EBITDA, Adjusted EBITDA, and Adjusted income should not be
construed as an inference that our future results will be
unaffected by unusual or nonrecurring items. The Company is
not able to provide a reconciliation of projected Adjusted EBITDA
and adjusted earnings per diluted share, where provided, to
expected results due to the unknown effect, timing and potential
significance of transaction-related expenses and the tax effect of
such expenses. (a) Represents the equity-based compensation
expense of Acadia.
(b) Represents transaction-related
expenses incurred by Acadia primarily related to acquisitions,
termination, restructuring and closing costs.
(c) Represents debt extinguishment costs recorded in
connection with the repricing amendments to the Amended and
Restated Credit Agreement in March 2018. (d) Represents tax
benefit related to the enactment of the Tax Cuts and Jobs Act.
(e) Represents the income tax effect of adjustments to
income based on tax rates of 16.6% and 15.9% for the three months
ended March 31, 2019 and 2018, respectively.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190430006131/en/
Gretchen HommrichDirector, Investor Relations(615) 861-6000
Acadia Healthcare (NASDAQ:ACHC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acadia Healthcare (NASDAQ:ACHC)
Historical Stock Chart
From Apr 2023 to Apr 2024